Skip to main content
SpringerLink
Log in

Konservative Therapie der erektilen Dysfunktion

Conservative therapy of erectile dysfunction

  • Leitthema
  • Published:
Der Urologe Aims and scope Submit manuscript

Zusammenfassung

Die erektile Dysfunktion (ED) ist mit einer Prävalenz von 19,2 % und einem steilen altersabhängigen Anstieg auf 53,4 % bei den über 70-Jährigen eine häufige Sexualstörung. Vor allem seit Einführung der Phosphodiesterase-5-Inhibitoren besteht die Möglichkeit einer einfach anwendbaren und gutverträglichen Therapie. Bei Therapieversagern können alternativ vasoaktive Substanzen auf verschiedene Art appliziert werden. Im Falle eines zusätzlichen Hypogonadismus ist eine Testosteronsubstitution indiziert. Parallel sollten immer eine Behandlung der Ursachen der ED und eine Änderung des Lebensstils mit der Elimination exogener Noxen erfolgen. Auch kann die Anwendung mechanischer Hilfsmittel als Einzel- bzw. Kombinationstherapie zu einer Verbesserung der Erektion führen. Dieser Artikel gibt eine kritische Übersicht über die aktuellen konservativen Therapieoptionen, nennt frühere erfolglose Anwendungsversuche und gibt einen Ausblick in zukünftige potenzielle Therapiekonzepte der ED.

Abstract

The erectile dysfunction (ED) with a prevalence of 19.2 % and a steep age-related increase up to 53.4 % in men over 70 years is a common sexual disorder. Especially after market launch of the phosphodiesterase 5 inhibitors the possibility of an easy-to-use and well-tolerated therapy is available. In case of nonresponse, vasoactive substances can be applied in different forms. In case of an additional hypogonadism, testosterone substitution is indicated. Simultaneously the causes of ED should always be treated, including a change of lifestyle with elimination of exogenous noxa. The use of mechanic tools as single or combination therapy can lead to improved erection. This article provides a critical overview of the latest conservative therapy options, it explains previous unsuccessful therapeutic trials and gives an outlook into potential ED therapy concepts of the future.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. ABDA-Datenbank, Datenbank der Bundesvereinigung Deutscher Apothekerverbände. Zugegriffen: 26. Feb. 2015

  2. Ahn GJ, Yu JY, Choi SM et al (2005) Chronic administration of phosphodiesterase 5 inhibitor improves erectile and endothelial function in a rat model of diabetes. Int J Androl 28(5):260–266

    Article  CAS  PubMed  Google Scholar 

  3. Braun M, Wassmer G, Klotz T et al (2000) Epidemiology of erectile dysfunction: results of the ‚Cologne Male Survey’. Int J Impot Res 12(6):305–311

    Article  CAS  PubMed  Google Scholar 

  4. Burnett AL (2008) Molecular pharmacotherapeutic targeting of PDE5 for preservation of penile health. J Androl 29(1):3–14

    Article  CAS  PubMed  Google Scholar 

  5. Buvat J, Costa P, Morlier D et al (1998) Double-blind multicentre study comparing alprostadil alphacyclodextrin with moxisylyte chlorhydrate in patients with chronic erectile dysfunction. J Urol 159(1):116–119

    Article  CAS  PubMed  Google Scholar 

  6. Chen J, Wollman Y, Chernichovsky T et al (1999) Effect of oral administration of high-dose nitric oxide donor L-arginine in men with organic erectile dysfunction: results of a double-blind, randomized, placebo-controlled study. BJU Int 83(3):269–273

    Article  CAS  PubMed  Google Scholar 

  7. Costa P, Potempa AJ (2012) Intraurethral alprostadil for erectile dysfunction: a review of the literature. Drugs 72(17):2243–2254

    Article  CAS  PubMed  Google Scholar 

  8. Dinsmore WW, Wyllie MG (2008) Vasoactive intestinal polypeptide/phentolamine for intracavernosal injection in erectile dysfunction. BJU Int 102(8):933–937

    Article  CAS  PubMed  Google Scholar 

  9. Dohle GR, Arver S, Bettocchi C et al (2012) Guidelines on Male hypogonadism. Eur Assoc Urol

  10. Earle CM, Keogh EJ, Wisniewski ZS et al (1990) Prostaglandin E1 therapy for impotence, comparison with papaverine. J Urol 143(1):57–59

    CAS  PubMed  Google Scholar 

  11. EMA (European Medicines Agency): Produktinformationen für die einzelnen Wirkstoffe unter. http://www.ema.europa.eu/ema/

  12. Fachinformation, BPI Service GmbH. http://www.fachinfo.de

  13. Fachinformation Vitaros®. http://www.hexal.de

  14. Facts & Comparisons (Datenbank). St. Louis, MO: Wolters Kluwer Health, Inc: 2009. http://online.factsandcomparisons.com

  15. Fallon B (1995) Intracavernous injection therapy for male erectile dysfunction. Urol Clin North Am 22(4):833–845

    CAS  PubMed  Google Scholar 

  16. Fulgham PF, Cochran JS, Denman JL et al (1998) Disappointing initial results with transurethral alprostadil for erectile dysfunction in a urology practice setting. J Urol 160(6 Pt 1):2041–2046

    Article  CAS  PubMed  Google Scholar 

  17. Gupta R, Kirschen J, Barrow RC II et al (1997) Predictors of success and risk factors for attrition in the use of intracavernous injection. J Urol 157(5):1681–1686

    Article  CAS  PubMed  Google Scholar 

  18. Godschalk MF, Chen J, Katz PG et al (1994) Treatment of erectile failure with prostaglandin E1: a double-blind, placebo-controlled, dose-response study. J Urol 151(6):1530–1532

    CAS  PubMed  Google Scholar 

  19. Hatzimouratidis K, Eardley I, Giuliano F et al (2014) Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Assoc Urology

  20. Heaton JP, Lording D, Liu SN et al (2001) Intracavernosal alprostadil is effective for the treatment of erectile dysfunction in diabetic men. Int J Impot Res 13(6):317–321

    Article  CAS  PubMed  Google Scholar 

  21. Iacono F, Giannella R, Somma P et al (2005) Histological alterations in cavernous tissue after radical prostatectomy. J Urol 173(5):1673–1676

    Article  PubMed  Google Scholar 

  22. Keogh EJ, Watters GR, Earle CM et al (1989) Treatment of impotence by intrapenile injections. A comparison of papaverine versus papaverine and phentolamine: a double-blind, crossover trial. J Urol 142(3):726–728

    CAS  PubMed  Google Scholar 

  23. Levine LA, Dimitriou RJ (2001) Vacuum constriction and external erection devices in erectile dysfunction. Urol Clin North Am 28(2):335–341

    Article  CAS  PubMed  Google Scholar 

  24. Levy A, Crowley T, Gingell C (2000) Non-surgical management of erectile dysfunction. Clin Endocrinol (Oxf) 52(3):253–260

    Google Scholar 

  25. Linet OI, Ogrinc FG (1996) Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group. N Engl J Med 334(14):873–877

    Article  CAS  PubMed  Google Scholar 

  26. Lue TF (2000) erectile dysfunction. N Engl J Med 342(24):1802–1813

    Article  CAS  PubMed  Google Scholar 

  27. Maclennan KM, Boshier A, Wilton LV et al (2006) Examination of the safety and use of apomorphine prescribed in general practice in England as a treatment for erectile dysfunction. BJU Int 98(1):125–131

    Article  CAS  PubMed  Google Scholar 

  28. Malavige LS, Levy JC (2009) Erectile dysfunction in diabetes mellitus. J Sex Med 5:1232–1247

    Article  Google Scholar 

  29. McMahon CG, Samali R, Johnson H (1999) Treatment of intracorporeal injection nonresponse with sildenafil alone or in combination with triple agent intracorporeal injection therapy. J Urol 162(6):1992–1997

    Article  CAS  PubMed  Google Scholar 

  30. McMahon C (2005) Comparison of efficacy, safety and tolerability of on-demand tadalafil and daily dosed tadalafil for the treatment of erectile dysfunction. J Sex Med 2(3):415–425

    Article  CAS  PubMed  Google Scholar 

  31. McMahon CN, Smith CJ, Shabsigh R (2006) Treating erectile dysfunction when PDE5 inhibitors fail. BMJ 332(7541):589–592

    Article  PubMed Central  PubMed  Google Scholar 

  32. McMurray JG, Feldman RA, Auerbach SM et al (2007) Long-term safety and effectiveness of sildenafil citrate in men with erectile dysfunction. Ther Clin Risk Manag 3(6):975–981

    PubMed Central  CAS  PubMed  Google Scholar 

  33. Mulhall JP, Daller M, Traish AM et al (1997) Intracavernosal forskolin: role in management of vasculogenic impotence resistant to standard 3-agent pharmacotherapy. J Urol 158(5):1752–1758

    Article  CAS  PubMed  Google Scholar 

  34. Mulhall JP, Jahoda AE, Ahmed A et al (2001) Analysis of the consistency of intraurethral prostaglandin E(1) (MUSE) during at-home use. Urology 58(2):262–266

    Article  CAS  PubMed  Google Scholar 

  35. Padma-Nathan H, Hellstrom WJ, Kaiser FE et al (1997) Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group. N Engl J Med 336(1):1–7

    Article  CAS  PubMed  Google Scholar 

  36. Porst H (1997) Transurethral alprostadil with MUSE versus intracavernous alprostadil: a comparative study in 103 patients with erectile dysfunction. Int J Impot Res 9:187–192

    Article  CAS  PubMed  Google Scholar 

  37. Porst H, Vardi Y, Akkus E et al (2010) Standards for clinical trials in male sexual dysfunctions. J Sex Med 7(1 Pt 2):414–444

    Article  CAS  PubMed  Google Scholar 

  38. Porst H, Burnett A, Brock G et al (2013) SOP conservative (medical and mechanical) treatment of erectile dysfunction. J Sex Med 10(1):130–171

    Article  CAS  PubMed  Google Scholar 

  39. Pratap SA, Rajender S (2012) Potent natural aphrodisiacs for the management of erectile dysfunction and male sexual debilities. Front Biosci (Schol Ed) 4:167–180

    Google Scholar 

  40. Raina R, Pahlajani G, Agarwal A et al (2007) The early use of transurethral alprostadil after radical prostatectomy potentially facilitates an earlier return of erectile function and successful sexual activity. BJU Int 100(6):1317–1321

    Article  PubMed  Google Scholar 

  41. Reid K, Surridge DH, Morales A et al (1987) Double-blind trial of yohimbine in treatment of psychogenic impotence. Lancet 2(8556):421–423

    Article  CAS  PubMed  Google Scholar 

  42. Riley AJ (1994) Yohimbine in the treatment of erectile disorder. Br J Clin Pract 48(3):133–136

    CAS  PubMed  Google Scholar 

  43. Rajfer J, Aliotta PJ, Steidle CP et al (2007) Tadalafil dosed once a day in men with erectile dysfunction: a randomized, double-blind, placebo-controlled study in the US. Int J Impot Res 19(1):95–103

    Article  CAS  PubMed  Google Scholar 

  44. Romero Otero J, García Gómez B, Medina Polo J et al (2014) Evaluation of current errors within the administration of phosphodiesterase-5 inhibitors after more than 10 years of use. Urology 83(6):1334–1338

    Article  Google Scholar 

  45. Sakakibara R, Hattori T, Uchiyama T et al (2000) Are alpha-blockers involved in lower urinary tract dysfunction in multiple system atrophy? A comparison of prazosin and moxisylyte. J Auton Nerv Syst 79:191–195

    Article  CAS  PubMed  Google Scholar 

  46. Sarosdy MF, Hudnall CH, Erickson DR et al (1989) A prospective double-blind trial of intracorporeal papaverine versus prostaglandin E1 in the treatment of impotence. J Urol 141(3):551–553

    CAS  PubMed  Google Scholar 

  47. Shabsigh R, Padma-Nathan H, Gittleman M et al (2000) Intracavernous alprostadil alfadex is more efficacious, better tolerated, and preferred over intraurethral alprostadil plus optional actis: a comparative, randomized, crossover, multicentre study. Urology 55(4):109–113

    Article  CAS  PubMed  Google Scholar 

  48. Tsertsvadze A, Fink HA, Yazdi F et al (2009) Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis. Ann Intern Med 51(9):650–661

    Article  Google Scholar 

  49. Urciuoli R, Cantisani TA, Carlini M et al (2004) Prostaglandin E1 for treatment of erectile dysfunction. Cochrane Database Syst Rev 2:CD001784

    PubMed  Google Scholar 

  50. Zumbé J, Porst H, Sommer F et al (2008) Comparable efficacy of once-daily versus on-demand vardenafil in men with mild-to-moderate erectile dysfunction: findings of the RESTORE study. Eur Urol 54(1):204–210

    Article  PubMed  Google Scholar 

Download references

Einhaltung ethischer Richtlinien

Interessenkonflikt. M. Trottmann J. Marcon, S. Pompe, D. Strobach, A.J. Becker und C.G. Stief geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.

Author information

Authors and Affiliations

  1. Urologische Klinik und Poliklinik, Ludwig-Maximilians-Universität München, Campus Großhadern, Marchioninistr. 15, 81377, München, Deutschland

    M. Trottmann, J. Marcon, A.J. Becker & C.G. Stief

  2. Apotheke des Klinikums der Ludwig-Maximilians-Universität München, Campus Großhadern, München, Deutschland

    S. Pompe & D. Strobach

Authors
  1. M. Trottmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Marcon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. Pompe
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D. Strobach
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A.J. Becker
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C.G. Stief
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Trottmann.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Trottmann, M., Marcon, J., Pompe, S. et al. Konservative Therapie der erektilen Dysfunktion. Urologe 54, 668–675 (2015). https://doi.org/10.1007/s00120-015-3794-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00120-015-3794-3

Schlüsselwörter

Keywords

Search

Navigation